Vanguard Global Advisers
ACTU

Vanguard Global Advisers’s Actuate Therapeutics ACTU Stock Holding History

Vanguard Global Advisers’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.81K Hold
5,102
– – ﹤0.01% 3514
2026
Q1 		$14K Buy
+5,102
New +$21.1K ﹤0.01% 3411

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's ACTU Position: Q2 2026 in Review

Vanguard Global Advisers held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 5,102 shares worth $7.81K. The position accounts for ﹤0.01% of the portfolio, ranked #3514.

Vanguard Global Advisers first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. The position peaked at $14K in Q1 2026. 62 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Vanguard Global Advisers held 5,102 shares of Actuate Therapeutics worth $7.81K as of Q2 2026.
  • Vanguard Global Advisers left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3514 holding.
  • Vanguard Global Advisers first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Actuate Therapeutics position peaked at $14K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.